Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
<b>Background:</b> The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around 50% of later-stage melanoma patients experiencing recurrence. As variable response...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Article |
| Langue: | anglais |
| Publié: |
MDPI AG
2025-06-01
|
| Collection: | Vaccines |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2076-393X/13/6/656 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|